Aurobindo Pharma submits ANDA for Empagliflozin
Aurobindo Pharma has submitted an Abbreviated New Drug Application (ANDA) for Empagliflozin.
| Drug | MOA / Company | Stage |
|---|---|---|
| Empagliflozin | Aurobindo Pharma | Lead |
Focal Asset
Empagliflozin
Company
Aurobindo Pharma
Indication
Diabetes / SGLT2 Inhibitor
Signal Score
8.2
Signal assessment
Signal strength
high
Confidence level
moderate
Why it matters
Aurobindo Pharma's submission of an ANDA for Empagliflozin signifies a new competitive entrant in the diabetes market, which could disrupt pricing and market share dynamics for existing SGLT2 inhibitors. Portfolio teams must evaluate the implications on their strategies as competition intensifies.
Recommended action
Humanexa recommends Monitor.
Analysis
Monitor the FDA's review timeline and any potential approval outcomes for ANDA212371.
Related companies & assets
Companies
Assets
Sources & Humanexa intelligence
Related Humanexa pages
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.